Australia approves new drug to slow Alzheimer’s progression

This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping together to form plaques, brown, that collect between neurons and disrupt cell function. Credit: AP

Alzheimer’s disease, the most common form of dementia, affects nearly 600,000 Australians. But there is renewed hope, with Australia’s Therapeutic Goods Administration approving a new medication that could offer relief to those living with the condition. Researchers say the drug represents a major breakthrough in the ongoing quest for more effective treatments.

Follow and Subscribe

Apple Podcasts YouTube Spotify Listnr Download (5.18MB)

Download the SBS Audio appAvailable on iOS and Android

Published 27 May 2025 9:51am

By Asha Abdi

Presented by Itee Dewan

Source: SBS

Share this with family and friends

Alzheimer’s disease, the most common form of dementia, affects nearly 600,000 Australians. But there is renewed hope, with Australia’s Therapeutic Goods Administration approving a new medication that could offer relief to those living with the condition. Researchers say the drug represents a major breakthrough in the ongoing quest for more effective treatments.

Find all our podcasts here at: SBS Hindi Podcast Collection.

You can also tune in to SBS Hindi at 5 pm on SBS South Asian on digital radio, on channel 305 on your television, via the SBS Audio app, or stream from our website.